ICAM1 and diffuse large B-cell lymphoma: The pretreatment of DLBCL-FRCs(c) with a titrated ICAM-1–blocking antibody significantly increased T cell migration, in keeping with elevated adhesion slowing down lymphocyte migration (Supplemental Figure 6N).